|
Retinoblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In familial cutaneous malignant melanoma (CMM), disruption of the retinoblastoma (pRB) pathway frequently occurs through inactivating mutations in the p16 (p16INK4A/CDKN2A/MTS1) gene or activating mutations in the G1-specific cyclin dependent kinase 4 gene (CDK4).
|
10732752 |
2000 |
|
Retinoblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We examined the expression levels of the p16, p15, p14, and retinoblastoma-susceptibility (RB) genes in primary prostate cancers and human prostate cancer cell lines, and correlated this with the DNA methylation levels of two loci in p16.
|
10797499 |
2000 |
|
Retinoblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Immortal HUCs and bladder cancer cell lines show either alteration of p16 or pRb, the product of the retinoblastoma (RB) TSG.
|
9436977 |
1998 |
|
Retinoblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our data indicate that in spite of low or absent p16 expression, genetic alterations of the p16 and Rb tumour suppressor genes are rare in endometrial carcinogenesis.
|
10071231 |
1999 |
|
Retinoblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In addition, we report for the first time that resistance of KRAS-mutant NSCLCs to MEK inhibitor is, at least partly, due to p16 mutation status, and we described a drug combination that efficiently reactivates the RB tumor suppressor pathway to trigger radiosensitizing effects, apoptosis, and cell-cycle arrest.
|
26728409 |
2016 |
|
Retinoblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
At present, the most useful methods of risk assessment are those performed on the following genes: BRCA1 and BRCA2 especially for hereditary breast and ovarian cancer, hMLH1 and hMSH2 for hereditary non polyposis colorectal cancer, APC for familial adenomatous polyposis, ret for medullary thyroid carcinoma, p53 for the Li-Fraumeni syndrome, p16 for melanoma and RB1 for retinoblastoma.
|
11205230 |
2001 |
|
Retinoblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
At least 1 of these abnormalities was found in 86% of the cases and a positive correlation was noted between p16 and pRb (P = 0.009).
|
18484097 |
2008 |
|
Retinoblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Studies on Radiation Therapy Oncology Group tissue samples have identified aberrant expression of p53, MDM2 (an E3 ubiquitin ligase that targets p53 for proteosomal degradation), and p16 (an upstream regulator of retinoblastoma and hence E2F1 in prostate cancer); abnormal expression of these biomarkers has been associated with clinical outcome after radiotherapy ± androgen deprivation therapy.
|
20832018 |
2010 |
|
Retinoblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
VRK1 protein levels increase in response to E2F1 and are reduced by retinoblastoma and p16.
|
16547155 |
2006 |
|
Retinoblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Univariate survival analysis revealed that the gene amplification of c-Myc (p = 0.008), Mdm2 (p = 0.020) and the gene deletion of p21 (p = 0.004), p16 (p = 0.015), and Rb1 (p = 0.028) were the independent predictive factor of 5-year OS for patients with TNBC.
|
24096545 |
2014 |
|
Retinoblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The inverse relationship between p16 and Rb was 62.5% (5/8).
|
17549378 |
2007 |
|
Retinoblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The inverse correlation of Rb and p16 defects in certain human tumors has led us to investigate the expression of p16 in human pituitary tumors as an indirect mechanism of Rb inactivation.
|
8653683 |
1996 |
|
Retinoblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The p16 gene expresses two alternative transcripts (p16alpha and p16beta) involved in tumor suppression via the retinoblastoma (Rb) or p53 pathways.
|
10498902 |
1999 |
|
Retinoblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Strong immunoreactivity for p16 protein was observed in both nuclei and cytoplasm of the tumor cells in eight out of nine cases of eccrine porocarcinomas, while RB expression was negative in these cases.
|
12207741 |
2002 |
|
Retinoblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although the underlying molecular-genetic pathways are not yet fully understood, the current results suggest functional reduction of the tumor suppressor genes Rb and p16 to be associated with progression of bladder cancer to a more malignant and aggressive behaviour.
|
15161057 |
2004 |
|
Retinoblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Several molecules such as retinoblastoma and p16 were raised as key factors in tumorigenesis and invasiveness.
|
21565925 |
2011 |
|
Retinoblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We further provide evidence for an interaction of SATB1 with the retinoblastoma (RB)/E2F pathway downstream of p16.
|
23686316 |
2013 |
|
Retinoblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Paraffin sections of 9 reactive lymph nodes and 43 low-grade and 60 high-grade malignant lymphomas were reacted with antibodies against pRB and p16.
|
9620022 |
1998 |
|
Retinoblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this phase II trial, patients with metastatic platinum-refractory UC molecularly selected for p16 loss and intact Rb by tumour immunohistochemistry received palbociclib 125 mg p.o. daily for 21 days of a 28-day cycle.
|
30293995 |
2018 |
|
Retinoblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Alterations of the retinoblastoma and p16 pathway correlate with promoter methylation in malignant fibrous histiocytomas.
|
17094467 |
2006 |
|
Retinoblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The results showed a decline in the expression of SOX2, P16 and P27 after miR-340 over-expression, whereas we observed an increase in the expression of cyclin A2, CDK2, SOX17, P18, SMAD 4 and RB.
|
27229858 |
2017 |
|
Retinoblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Retinoblastoma (Rb) downregulation by HPV E7 results in p16 upregulation.
|
16401683 |
2006 |
|
Retinoblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These data suggest that p16 inactivation is selected as the most effective mechanism of blocking the cyclin D-Rb pathway during the evolution of an invasive cancer from precursor lesions.
|
10535995 |
1999 |
|
Retinoblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The growth suppressing activity of the retinoblastoma suspectibility gene product, pRb, is down regulated by cyclin-dependent kinases 4 and 6 (CDK4 and CDK6) whose kinase activity is negatively regulated by CDK inhibitors of the p16 family.
|
8570224 |
1996 |
|
Retinoblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In the TBP-2-overexpressing cells, a G1 arrest was observed in association with an increase of p16 expression and reduction of retinoblastoma phosphorylation.
|
14983878 |
2004 |